Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 6NIH 2NETWORK 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 94Other hematologic neoplasm 18Sarcoma 7CNS 4Genitourinary 3Thoracic 2Plasma cell 2Tumor-Agnostic 1Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cisplatin 15Fluorouracil 14Cyclophosphamide 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Vincristine × Dermatologic × Clear all
NCT00145041 2019-12-12

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

Acrotech Biopharma Inc.

Phase 1 Completed
7 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡